ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 889

Central Nervous System Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Retrospective Analysis of 26 Cases and Review of the Literature

Raphael André1, Chahéra Khouatra2, Jean-Luc Saraux3, Francois Maurier4, Gilles Blaison5, Boris Bienvenu6, Pascal Cathebras7, Nathalie Costedoat-Chalumeau8, Robin Dhote9, Aurélie Foucher10, Helder Gil11, Joelle Lapouarie12, David Launay13, Edouard Pertuiset14, Valentine Loustau15, Thierry Zenone16, Claire Le Jeunne17, Luc Mouthon18, Loïc Guillevin19 and Benjamin Terrier20, 1Cochin Hospital, Paris, France, 2CHU Lyon, Lyon, France, 3CH Eaubonne, Eaubonne, France, 4HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 5Internal medicine, CHR, Colmar, France, 6Internal Medicine, Hospital Caen, Caen, France, 7Internal Medicine, University Hospital St Etienne, St Etienne, France, 8Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 9Internal Medicine, Hospital Avicenne, Bobigny, France, 10CHU, Saint Pierre de la Réunion, France, 11CHU, Besancon, France, 12CHU, Pau, France, 13Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, 14CH René Dubos, Pontoise, France, 15Hôpital Henri Mondor, Créteil, France, 16CH de Valence, Valence, France, 17Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, 18Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, 19Internal Medicine, Hopital Cochin, Paris, France, 20Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: central nervous system involvement, Churg-Strauss syndrome, Neurologic involvement and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma, blood and tissue eosinophilia, vasculitis-related peripheral neuropathy, glomerulonephritis or skin symptoms. Although peripheral nervous system involvement occurs frequently, usually as multiple mononeuropathy, exceptional central nervous system (CNS) disease, severe and associated with poor prognosis according to the 1996 Five-Factor Score, has been described. This study aimed to describe CNS involvement in EGPA.

Methods: This retrospective, observational, multicenter study included patients with EGPA meeting ACR criteria and/or Chapel Hill definitions, and CNS involvement affecting cranial nerves, brain or spinal cord. We also undertook a systematic literature review.

Results:

We analyzed 26 patients (50% women, mean age 57±15 years) and 62 reported EGPA-CNS cases (52% women, mean age 47±16 years). At EGPA diagnosis, their main manifestations included: asthma in 97%, hypereosinophilia in 98% with median eosinophil count 7500/mm3, sinonasal abnormalities in 66%, peripheral neuropathy in 55%, pulmonary infiltrates in 52% and biopsy with eosinophilic infiltration in 46%; 41% had cardiac involvement, including myocarditis (27%),  pericarditis (16%), endomyocardial fibrosis (8%) and cardiac arrhythmia (2%). 38/71 (55%) were ANCA-positive, with a perinuclear-labeling pattern and/or anti-MPO specificity.

The CNS was involved in 86% at EGPA diagnosis, preceded EGPA in 2%, and occurred during follow-up in 12% after a median of 24 months. The main neurological signs were: 46 (52%) ischemic cerebrovascular lesions, 21 (24%) intracerebral hemorrhage or subarachnoid hemorrhage, 28 (32%) visual acuity loss (15 with retrobulbar optic neuritis, 10 occluded central retinal artery or 4 cortical blindness), and 18 (20%) cranial nerves palsies; 25 patients had ≥1 of these clinical CNS signs.

Patients with visual acuity loss and cranial nerve palsies had similar clinical-biological parameters. In contrast, patients with intracerebral or subarachnoid hemorrhage compared to those with ischemic cerebrovascular lesions were younger (43 vs 52 years), had less frequent myocarditis (10% vs 35%), more frequent peripheral neuropathy (67% vs 41%), glomerulonephritis (29% vs 13%) and ANCA (79% vs 52%); and had higher median eosinophil counts (12850 vs 7500/mm3).

All patients were treated with corticosteroids, associated with cyclophosphamide in 63%, azathioprine in 4% or methotrexate in 1%. Among the 81 patients with assessable neurological responses, 43% had complete responses without sequelae, 43% had partial responses with long-term sequelae and 14% refractory disease. After a mean follow-up of 36 months, 11 patients died, half of intracerebral hemorrhages.

Conclusion: The main EGPA-CNS manifestations form 4 distinct neurological pictures: ischemic lesions, intracerebral hemorrhages, cranial nerve palsies and optic neuritis- or central retinal artery occlusion-related visual acuity loss. Such manifestation should prompt practitioners to consider an EGPA diagnosis in such conditions. Neurological sequelae were common.


Disclosure: R. André, None; C. Khouatra, None; J. L. Saraux, None; F. Maurier, None; G. Blaison, None; B. Bienvenu, None; P. Cathebras, None; N. Costedoat-Chalumeau, None; R. Dhote, None; A. Foucher, None; H. Gil, None; J. Lapouarie, None; D. Launay, None; E. Pertuiset, None; V. Loustau, None; T. Zenone, None; C. Le Jeunne, None; L. Mouthon, None; L. Guillevin, None; B. Terrier, None.

To cite this abstract in AMA style:

André R, Khouatra C, Saraux JL, Maurier F, Blaison G, Bienvenu B, Cathebras P, Costedoat-Chalumeau N, Dhote R, Foucher A, Gil H, Lapouarie J, Launay D, Pertuiset E, Loustau V, Zenone T, Le Jeunne C, Mouthon L, Guillevin L, Terrier B. Central Nervous System Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Retrospective Analysis of 26 Cases and Review of the Literature [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/central-nervous-system-involvement-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-retrospective-analysis-of-26-cases-and-review-of-the-literature/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/central-nervous-system-involvement-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-retrospective-analysis-of-26-cases-and-review-of-the-literature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology